These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33830945)

  • 1. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation.
    Xu H; Van der Jeught K; Zhou Z; Zhang L; Yu T; Sun Y; Li Y; Wan C; So KM; Liu D; Frieden M; Fang Y; Mosley AL; He X; Zhang X; Sandusky GE; Liu Y; Meroueh SO; Zhang C; Wijeratne AB; Huang C; Ji G; Lu X
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33830945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation.
    Fang Y; Wang L; Wan C; Sun Y; Van der Jeught K; Zhou Z; Dong T; So KM; Yu T; Li Y; Eyvani H; Colter AB; Dong E; Cao S; Wang J; Schneider BP; Sandusky GE; Liu Y; Zhang C; Lu X; Zhang X
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 32990678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity.
    Hong E; Usiskin IM; Bergamaschi C; Hanlon DJ; Edelson RL; Justesen S; Pavlakis GN; Flavell RA; Fahmy TM
    J Biol Chem; 2016 Apr; 291(17):8931-50. PubMed ID: 26719339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory.
    Dai J; Liu B; Caudill MM; Zheng H; Qiao Y; Podack ER; Li Z
    Cancer Immun; 2003 Jan; 3():1. PubMed ID: 12747743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.
    Busenhart P; Montalban-Arques A; Katkeviciute E; Morsy Y; Van Passen C; Hering L; Atrott K; Lang S; Garzon JFG; Naschberger E; Hartmann A; Rogler G; Stürzl M; Spalinger MR; Scharl M
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity.
    Wang Z; Chen J; Hu J; Zhang H; Xu F; He W; Wang X; Li M; Lu W; Zeng G; Zhou P; Huang P; Chen S; Li W; Xia LP; Xia X
    J Clin Invest; 2019 Aug; 129(11):4850-4862. PubMed ID: 31408442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity.
    Zebertavage LK; Alice A; Crittenden MR; Gough MJ
    Sci Rep; 2020 Apr; 10(1):7376. PubMed ID: 32355214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
    Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
    Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.
    Such L; Zhao F; Liu D; Thier B; Le-Trilling VTK; Sucker A; Coch C; Pieper N; Howe S; Bhat H; Kalkavan H; Ritter C; Brinkhaus R; Ugurel S; Köster J; Seifert U; Dittmer U; Schuler M; Lang KS; Kufer TA; Hartmann G; Becker JC; Horn S; Ferrone S; Liu D; Van Allen EM; Schadendorf D; Griewank K; Trilling M; Paschen A
    J Clin Invest; 2020 Aug; 130(8):4266-4281. PubMed ID: 32427578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens.
    Kines RC; Thompson CD; Spring S; Li Z; de Los Pinos E; Monks S; Schiller JT
    Cancer Immunol Res; 2021 Jun; 9(6):693-706. PubMed ID: 33853825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
    Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
    Front Immunol; 2019; 10():1505. PubMed ID: 31333652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
    Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
    Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells.
    Burbach BJ; O'Flanagan SD; Shao Q; Young KM; Slaughter JR; Rollins MR; Street TJL; Granger VE; Beura LK; Azarin SM; Ramadhyani S; Forsyth BR; Bischof JC; Shimizu Y
    Nat Commun; 2021 Jun; 12(1):3862. PubMed ID: 34162858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development.
    Aguilar LK; Guzik BW; Aguilar-Cordova E
    J Cell Biochem; 2011 Aug; 112(8):1969-77. PubMed ID: 21465529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dendritic cell population generated by a fusion of GM-CSF and IL-21 induces tumor-antigen-specific immunity.
    Williams P; Bouchentouf M; Rafei M; Romieu-Mourez R; Hsieh J; Boivin MN; Yuan S; Forner KA; Birman E; Galipeau J
    J Immunol; 2010 Dec; 185(12):7358-66. PubMed ID: 21076067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
    Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW
    Front Immunol; 2018; 9():822. PubMed ID: 29755461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.